Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administ...

Full description

Saved in:
Bibliographic Details
Main Authors: Francini, Filippo, Pascucci, Alessandra, Francini, Edoardo, Bargagli, Gianluca, Conca, Raffaele, Licchetta, Antonella, Roviello, Giandomenico, Martellucci, Ignazio, Chiriacò, Giorgio, Miano, Salvatora Tindara, Marzocca, Giuseppe, Manganelli, Antonio, Ponchietti, Roberto, Savelli, Vinno, Petrioli, Roberto
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2011
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://ncbi.nlm.nih.gov/pubmed/22096653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/258689
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items